Declining ALS Patients Are Waiting On The FDA...

By many metrics, Meta is falling behind in the AI race. So CEO Mark Zuckerberg is building one of the largest data centers in the world — a facility the size of about 3,000 football fields in one of the poorest regions in the US. On today’s Big Take podcast, host Sarah Holder sit ...  Show more

President Rodrigo Paz ended 20 years of socialist rule in Bolivia with promises of unity, democracy and prosperity — and plans to tap the country’s mineral wealth. But when host David Gura went to Bolivia to interview the president, he found a harsher reality: demonstrators block ...  Show more

ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a co ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

For decades, the law has sought to restrain nursing homes from trying to control the behavior of dementia patients with antipsychotic drugs, which are known to have adverse health effects. 

An alarming rise in schizophrenia diagnoses suggests some homes have found a way ...